Andrx Relinquishes Exclusivity Rights To 150mg Generic Zyban

Law360, New York (May 28, 2004, 12:00 AM EDT) -- Generic drug maker Andrx Corp. has relinquished its right to a 180-day period of marketing exclusivity for the 150mg strength of GlaxoSmithKline’s smoking cessation drug Zyban, under a deal in which Andrx will share its profits on the drug with Israeli drug maker Teva.

As a result of this relinquishment, other companies who have submitted Abbreviated New Drug Applications (ANDAs) for this strength can receive approval from the U.S. Food and Drug Administration (FDA) to market their products, Andrx said.

Impax Corporation's ANDA for this strength...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.